Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Klink

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Anti-Cancer Drugs|January 12, 2000
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumorsR A Newman, J Kim, B M Newman, et al.
Microbiology and Immunology|October 21, 1999
The production of nitric oxide and tumor necrosis factor by murine macrophages infected with mycobacterial strains differing by hemolytic activityW Rudnicka, M Brzychcy, M Klink, et al.
Seminars in Surgical Oncology|January 1, 1988
Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-RoussyJ P Droz, C Theodore, M Ghosn, et al.
Anti-Cancer Drugs|February 1, 1996
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patientsD Abigerges, J P Armand, G G Chabot, et al.
Journal of the National Cancer Institute|January 5, 1994
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitroJ R Eckardt, H A Burris, J G Kuhn, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Anti-Cancer Drugs|January 12, 2000
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumorsR A Newman, J Kim, B M Newman, et al.
Microbiology and Immunology|October 21, 1999
The production of nitric oxide and tumor necrosis factor by murine macrophages infected with mycobacterial strains differing by hemolytic activityW Rudnicka, M Brzychcy, M Klink, et al.
Seminars in Surgical Oncology|January 1, 1988
Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-RoussyJ P Droz, C Theodore, M Ghosn, et al.
Anti-Cancer Drugs|February 1, 1996
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patientsD Abigerges, J P Armand, G G Chabot, et al.
Journal of the National Cancer Institute|January 5, 1994
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitroJ R Eckardt, H A Burris, J G Kuhn, et al.
Pageof 4